A public rulebook for when an external or synthetic control arm is acceptable
Sometimes a trial cannot randomise, so the new drug is compared with past patients' records. Clear published rules on when that is allowed, and how it must be done, would replace case-by-case guesswork.
Regulators publish a binding checklist for externally controlled trials: pre-registration of the comparator cohort and analysis before unblinding; target-trial emulation framing; minimum data quality (endpoint ascertainment, line of therapy, index date); quantitative bias analysis and tipping-point reporting; and the settings where it is acceptable (rare disease, effect size large relative to plausible confounding, randomisation infeasible). Submissions meeting the rulebook receive predictable review.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaStandards for external control arms built from federated real-world data
Shares Weak real-world evidence and registries, Real-world evidence, Rare and paediatric cancers without markets, Trial design, endpoints and cost.
- IdeaA pre-registered standard for emulating trials with real-world data
Shares Hazard ratio (HR), Weak real-world evidence and registries, Real-world evidence, Trial design, endpoints and cost.
- IdeaEvery patient on an accelerated-approval drug enrolled in a registry until confirmation
Shares Accelerated approval, Weak real-world evidence and registries, Real-world evidence.
- IdeaCheap long-term survival follow-up by linking trial participants to registries
Shares Accelerated approval, Weak real-world evidence and registries, Trial design, endpoints and cost.
- IdeaAfter approval, a pragmatic trial in the patients the pivotal trial excluded
Shares Weak real-world evidence and registries, Real-world evidence, Trial design, endpoints and cost.
- IdeaRegistry-based randomised trials for oncology comparative effectiveness
Shares Weak real-world evidence and registries, Real-world evidence, Trial design, endpoints and cost.
- IdeaBayesian shrinkage for subgroup claims to stop false 'works in this group' stories
- IdeaAgree in advance how to borrow evidence between similar rare cancers
Shares Hazard ratio (HR), Rare and paediatric cancers without markets, Trial design, endpoints and cost.